Lake Zurich, Ill., September 11, 2015 – Fresenius Kabi USA announced today it has introduced the anti-infective Moxifloxacin Injection 400 mg per 250 mL in Freeflex® bags. This is a first-to-market alternative for this injectable drug which had previously been available only from the innovator.
Fresenius Kabi is a global health care company that specializes in life-saving medicines and technologies for infusion, transfusion and clinical nutrition.
Moxifloxacin is the third premix product Fresenius Kabi has introduced in the United States since 2013 using the company’s proprietary Freeflex delivery system. Freeflex is a non-PVC and non-DEHP flexible bag for infusion solutions using patented port technology and clear labeling.
"Fresenius Kabi is pleased to offer this first and only alternative to Avelox Injection for our customers and the patients they serve,” said John Ducker, president and CEO of Fresenius Kabi USA. “The introduction of Moxifloxacin expands both our leading anti-infective portfolio and our ready-to-use intravenous offerings in the U.S."
Moxifloxacin Injection Important Safety Information (ISI)
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.